<p>OraSure（OSUR）已举行其第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的_ETF_ AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
<p>在最近的财报电话会议上，OraSure Technologies 呈现出混合的情绪，强调了战略进展和财务挑战。公司强调了其战略举措，包括收购 BioMedomics 和续签重要的公共卫生项目。然而，美国和国际诊断部门的显著收入下降，以及持续的财务亏损，暗示未来一年将面临挑战。</p>
<h2>战略转型与增长计划</h2>
<p>OraSure 继续推进其战略转型，专注于多样化产品供应，并投资于研发、收购和合作伙伴关系。这些努力旨在为公司到 2026 年实现增长奠定基础，表明了长期扩展和创新的愿景。</p>
<h2>BioMedomics 收购</h2>
<p>电话会议的一个关键亮点是 OraSure 与 BioMedomics 达成的最终收购协议。这项收购将通过引入 Sickle SCAN（一种快速检测镰状细胞病的测试）来增强 OraSure 的诊断产品组合。此举预计将利用现有的国际销售渠道，可能提升公司的市场存在感。</p>
<h2>“一起带我回家” 计划的续签</h2>
<p>HIV 自测项目 “一起带我回家” 的续签是另一个重要话题。该项目由联邦政府资助，并获得两党支持，此次续签确保了 OraSure 公共卫生倡议的持续收入和支持，强化了公司对公共卫生的承诺。</p>
<h2>HEMAcollect PROTEIN 的积极反馈</h2>
<p>自推出以来，HEMAcollect PROTEIN 获得了客户的积极反馈，预计将支持 2026 年蛋白质组学市场的势头。这一积极反响表明该领域潜在的增长机会。</p>
<h2>强劲的财务状况</h2>
<p>尽管面临挑战，OraSure 仍保持强劲的财务状况，第三季度结束时现金及现金等价物为 2.16 亿美元，且无债务。这一财务稳定性支持公司投资于增长机会的战略，为应对当前市场挑战提供了缓冲。</p>
<h2>国际诊断收入下降</h2>
<p>财报电话会议强调，国际诊断收入预计将比 2024 年下降 20%。这一下降归因于订单速度放缓和国家健康项目资金变化，给公司带来了重大挑战。</p>
<h2>美国诊断收入下降</h2>
<p>预计美国诊断部门的收入将在 2025 年相比 2024 年出现低个位数百分比的下降。这一下降受到人员减少和联邦机构预算不确定性的影响，影响了该部门的表现。</p>
<h2>样本管理收入挑战</h2>
<p>样本管理收入预计将与 2024 年持平，主要是由于来自主要消费者基因客户的订单下降。这一停滞突显了在这一领域维持增长的挑战。</p>
<h2>持续的财务亏损</h2>
<p>OraSure 报告第三季度 GAAP 运营亏损为 1610 万美元，非 GAAP 运营亏损为 1270 万美元，反映出持续的财务挑战。这些亏损凸显了改善财务表现所需的战略调整。</p>
<h2>前瞻性指导</h2>
<p>展望未来，OraSure 为即将到来的季度提供了指导。公司预计第四季度收入将在 2500 万至 2800 万美元之间，运营费用约为 2000 万美元。此外，1000 万美元将用于创新投资。国际诊断业务预计将比 2024 年下降约 20%，而美国诊断收入预计将在 3000 万至 3500 万美元之间，略低于 2024 年。样本管理业务预计将保持平稳，收入在 3000 万至 4000 万美元之间。</p>
<p>总之，OraSure Technologies 的财报电话会议描绘了战略雄心与财务挑战交织的图景。尽管公司在产品多样化和公共卫生倡议方面取得了进展，但显著的收入下降和持续的财务亏损仍然是需要解决的障碍。然而，OraSure 强劲的财务状况和战略收购为未来潜在的增长提供了基础。</p>

奥瑞许科技

<p>OraSure Technologies (OSUR) 举行了第三季度财报电话会议，揭示了一系列战略进展和财务挑战。主要亮点包括收购 BioMedomics 以增强其诊断产品组合，续签 HIV 自测项目，以及对 HEMAcollect PROTEIN 的积极反馈。然而，公司在美国和国际诊断部门面临显著的收入下降，并报告了持续的财务亏损。尽管面临这些挑战，OraSure 仍保持强劲的财务状况，拥有 2.16 亿美元的现金和零债务，支持其长期增长战略</p>

<p>Orasure ((OSUR)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>OraSure（OSUR）已举行其第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的_ETF_ AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
</div><p>During the recent earnings call, OraSure Technologies presented a mixed sentiment, highlighting both strategic advancements and financial challenges. The company emphasized its strategic initiatives, including the acquisition of BioMedomics and the renewal of vital public health programs. However, significant revenue declines in both U.S. and International Diagnostics segments, along with ongoing financial losses, suggest a challenging year ahead.</p>
<div class="lb-trans"><p>在最近的财报电话会议上，OraSure Technologies 呈现出混合的情绪，强调了战略进展和财务挑战。公司强调了其战略举措，包括收购 BioMedomics 和续签重要的公共卫生项目。然而，美国和国际诊断部门的显著收入下降，以及持续的财务亏损，暗示未来一年将面临挑战。</p>
</div><h2>Strategic Transformation and Growth Plans</h2>
<div class="lb-trans"><h2>战略转型与增长计划</h2>
</div><p>OraSure continues to push forward with its strategic transformation, focusing on diversifying its product offerings and investing in research and development, acquisitions, and partnerships. These efforts are aimed at positioning the company for growth by 2026, indicating a long-term vision for expansion and innovation.</p>
<div class="lb-trans"><p>OraSure 继续推进其战略转型，专注于多样化产品供应，并投资于研发、收购和合作伙伴关系。这些努力旨在为公司到 2026 年实现增长奠定基础，表明了长期扩展和创新的愿景。</p>
</div><h2>BioMedomics Acquisition</h2>
<div class="lb-trans"><h2>BioMedomics 收购</h2>
</div><p>A key highlight of the call was OraSure’s definitive agreement to acquire BioMedomics. This acquisition is set to enhance OraSure’s Diagnostic portfolio with the inclusion of Sickle SCAN, a rapid test for sickle cell disease. The move is expected to capitalize on existing international sales channels, potentially boosting the company’s market presence.</p>
<div class="lb-trans"><p>电话会议的一个关键亮点是 OraSure 与 BioMedomics 达成的最终收购协议。这项收购将通过引入 Sickle SCAN（一种快速检测镰状细胞病的测试）来增强 OraSure 的诊断产品组合。此举预计将利用现有的国际销售渠道，可能提升公司的市场存在感。</p>
</div><h2>Renewal of Together Take Me Home Program</h2>
<div class="lb-trans"><h2>“一起带我回家” 计划的续签</h2>
</div><p>The renewal of the HIV self-test program, “Together Take Me Home,” was another significant topic. Funded by the federal government with bipartisan support, this renewal ensures continued revenue and support for OraSure’s public health initiatives, reinforcing the company’s commitment to public health.</p>
<div class="lb-trans"><p>HIV 自测项目 “一起带我回家” 的续签是另一个重要话题。该项目由联邦政府资助，并获得两党支持，此次续签确保了 OraSure 公共卫生倡议的持续收入和支持，强化了公司对公共卫生的承诺。</p>
</div><h2>Positive Feedback on HEMAcollect PROTEIN</h2>
<div class="lb-trans"><h2>HEMAcollect PROTEIN 的积极反馈</h2>
</div><p>Since its launch, HEMAcollect PROTEIN has garnered positive feedback from customers, which is expected to support momentum in the proteomics market for 2026. This positive reception indicates potential growth opportunities in this sector.</p>
<div class="lb-trans"><p>自推出以来，HEMAcollect PROTEIN 获得了客户的积极反馈，预计将支持 2026 年蛋白质组学市场的势头。这一积极反响表明该领域潜在的增长机会。</p>
</div><h2>Strong Financial Position</h2>
<div class="lb-trans"><h2>强劲的财务状况</h2>
</div><p>Despite the challenges, OraSure maintains a strong financial position, ending Q3 with $216 million in cash and cash equivalents and zero debt. This financial stability supports the company’s strategy of investing in growth opportunities, providing a buffer against current market challenges.</p>
<div class="lb-trans"><p>尽管面临挑战，OraSure 仍保持强劲的财务状况，第三季度结束时现金及现金等价物为 2.16 亿美元，且无债务。这一财务稳定性支持公司投资于增长机会的战略，为应对当前市场挑战提供了缓冲。</p>
</div><h2>Revenue Decline in International Diagnostics</h2>
<div class="lb-trans"><h2>国际诊断收入下降</h2>
</div><p>The earnings call highlighted a projected 20% decline in International Diagnostics revenue compared to 2024. This decline is attributed to a slower order pace and changes in national health program funding, presenting a significant challenge for the company.</p>
<div class="lb-trans"><p>财报电话会议强调，国际诊断收入预计将比 2024 年下降 20%。这一下降归因于订单速度放缓和国家健康项目资金变化，给公司带来了重大挑战。</p>
</div><h2>U.S. Diagnostics Revenue Decline</h2>
<div class="lb-trans"><h2>美国诊断收入下降</h2>
</div><p>The U.S. Diagnostics segment is expected to experience a low single-digit percentage decline in revenue for 2025 compared to 2024. This decline is influenced by staffing reductions and budgetary uncertainties in federal agencies, impacting the segment’s performance.</p>
<div class="lb-trans"><p>预计美国诊断部门的收入将在 2025 年相比 2024 年出现低个位数百分比的下降。这一下降受到人员减少和联邦机构预算不确定性的影响，影响了该部门的表现。</p>
</div><h2>Sample Management Revenue Challenges</h2>
<div class="lb-trans"><h2>样本管理收入挑战</h2>
</div><p>Sample Management revenues are anticipated to remain flat compared to 2024, primarily due to a decline in orders from a major consumer genetics customer. This stagnation highlights the challenges in maintaining growth in this area.</p>
<div class="lb-trans"><p>样本管理收入预计将与 2024 年持平，主要是由于来自主要消费者基因客户的订单下降。这一停滞突显了在这一领域维持增长的挑战。</p>
</div><h2>Continued Financial Losses</h2>
<div class="lb-trans"><h2>持续的财务亏损</h2>
</div><p>OraSure reported a GAAP operating loss of $16.1 million and a non-GAAP operating loss of $12.7 million for Q3, reflecting ongoing financial challenges. These losses underscore the need for strategic adjustments to improve financial performance.</p>
<div class="lb-trans"><p>OraSure 报告第三季度 GAAP 运营亏损为 1610 万美元，非 GAAP 运营亏损为 1270 万美元，反映出持续的财务挑战。这些亏损凸显了改善财务表现所需的战略调整。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Looking ahead, OraSure provided guidance for the upcoming quarters. The company expects fourth-quarter revenue to range between $25 to $28 million, with operating expenses around $20 million. Additionally, $10 million is earmarked for innovation investments. The International Diagnostics business is projected to decline by approximately 20% compared to 2024, while U.S. Diagnostics revenue is expected to be in the low to mid-$30 million range, slightly down from 2024. The Sample Management business is anticipated to remain flat, with revenues in the high $30 million range.</p>
<div class="lb-trans"><p>展望未来，OraSure 为即将到来的季度提供了指导。公司预计第四季度收入将在 2500 万至 2800 万美元之间，运营费用约为 2000 万美元。此外，1000 万美元将用于创新投资。国际诊断业务预计将比 2024 年下降约 20%，而美国诊断收入预计将在 3000 万至 3500 万美元之间，略低于 2024 年。样本管理业务预计将保持平稳，收入在 3000 万至 4000 万美元之间。</p>
</div><p>In summary, OraSure Technologies’ earnings call painted a picture of strategic ambition tempered by financial challenges. While the company is making strides in product diversification and public health initiatives, significant revenue declines and continued financial losses present hurdles that need addressing. Nevertheless, OraSure’s strong financial position and strategic acquisitions offer a foundation for potential future growth.</p>
<div class="lb-trans"><p>总之，OraSure Technologies 的财报电话会议描绘了战略雄心与财务挑战交织的图景。尽管公司在产品多样化和公共卫生倡议方面取得了进展，但显著的收入下降和持续的财务亏损仍然是需要解决的障碍。然而，OraSure 强劲的财务状况和战略收购为未来潜在的增长提供了基础。</p>
</div>

奥瑞许科技财报电话会议：面对财务挑战的战略举措